Alteogen - Public Comps and Valuation Multiples

Alteogen Overview

About Alteogen

Alteogen Inc Inc is engaged in the development and manufacture of next-generation biopharmaceuticals using NexP Fusion Technology. It also develops & markets biobetters and biosimilars by partnerships with pharmaceutical companies. It focuses on the areas such as biobetters, a proprietary antibody-drug conjugate, and antibody biosimilars with complexity.

Founded

2008

HQ

Employees

n/a

Website

alteogen.com

Sectors

Biopharmaceuticals
BioTech

Financials

LTM Revenue $147M

LTM EBITDA $80.8M

EV

$15.9B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Alteogen Financials

As of September 2025, Alteogen reported last 12-month revenue of $147M and EBITDA of $80.8M.

In the same period, Alteogen generated $118M in LTM gross profit and $74.1M in net income.

See Alteogen valuation multiples based on analyst estimates

Alteogen P&L

In the most recent fiscal year, Alteogen reported revenue of $72.0M and EBITDA of $28.1M.

Alteogen expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Alteogen valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$147M	XXX	$72.0M	XXX	XXX	XXX
Gross Profit	$118M	XXX	$44.8M	XXX	XXX	XXX
Gross Margin	80%	XXX	62%	XXX	XXX	XXX
EBITDA	$80.8M	XXX	$28.1M	XXX	XXX	XXX
EBITDA Margin	55%	XXX	39%	XXX	XXX	XXX
EBIT	$84.5M	XXX	$17.8M	XXX	XXX	XXX
EBIT Margin	57%	XXX	25%	XXX	XXX	XXX
Net Profit	$74.1M	XXX	$43.6M	XXX	XXX	XXX
Net Margin	50%	XXX	61%	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Alteogen including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $147M. EBITDA for the last twelve months was $80.8M. In the most recent fiscal year, Alteogen achieved $72.0M in revenue and $28.1M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$147M	Analyst estimates available to subscribers	$72.0M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$118M	Analyst estimates available to subscribers	$44.8M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	79.9% gross margin	Analyst estimates available to subscribers	62.3% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$80.8M	Analyst estimates available to subscribers	$28.1M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	54.8% EBITDA margin	Analyst estimates available to subscribers	39.0% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$84.5M	Analyst estimates available to subscribers	$17.8M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	57.3% EBIT margin	Analyst estimates available to subscribers	24.7% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$74.1M	Analyst estimates available to subscribers	$43.6M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	50.3% net profit margin	Analyst estimates available to subscribers	60.5% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Alteogen

This financial data table provides comprehensive performance metrics for Alteogen, a company based in South Korea. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Alteogen generated $147M in revenue over the last twelve months.
The company achieved $80.8M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $118M.
Net income over the last twelve months reached $74.1M.

Fiscal Year Performance

In the most recent fiscal year, Alteogen reported $72.0M in total revenue.
Fiscal year EBITDA was $28.1M.
The company maintained a gross profit margin of 62.3% in the most recent fiscal year.
EBITDA margin for the fiscal year was 39.0%.
Net profit margin reached 60.5% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Alteogen. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Alteogen Stock Performance

Alteogen has current market cap of KRW 23.14T (or $16.2B), and EV of KRW 22.76T (or $15.9B).

Market Cap Evolution

Alteogen Stock Data

As of October 17, 2025, Alteogen's stock price is KRW 433000 (or $303).

See Alteogen trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$15.9B	$16.2B	XXX	XXX	XXX	XXX	$1.38

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Alteogen Valuation Multiples

Alteogen's trades at 221.3x EV/Revenue multiple, and 567.1x EV/EBITDA.

See valuation multiples for Alteogen and 15K+ public comps

Alteogen Financial Valuation Multiples

As of October 17, 2025, Alteogen has market cap of $16.2B and EV of $15.9B.

Equity research analysts estimate Alteogen's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Alteogen has a P/E ratio of 218.5x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$16.2B	XXX	$16.2B	XXX	XXX	XXX
EV (current)	$15.9B	XXX	$15.9B	XXX	XXX	XXX
EV/Revenue	108.0x	XXX	221.3x	XXX	XXX	XXX
EV/EBITDA	197.1x	XXX	567.1x	XXX	XXX	XXX
EV/EBIT	188.5x	XXX	895.9x	XXX	XXX	XXX
EV/Gross Profit	135.2x	XXX	n/a	XXX	XXX	XXX
P/E	218.5x	XXX	371.7x	XXX	XXX	XXX
EV/FCF	274.0x	XXX	795.9x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Alteogen Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Alteogen Margins & Growth Rates

Alteogen's last 12 month revenue growth is 119%

Alteogen's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.

Alteogen's rule of 40 is 120% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Alteogen's rule of X is 353% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Alteogen and other 15K+ public comps

Alteogen Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	119%	XXX	124%	XXX	XXX	XXX
EBITDA Margin	55%	XXX	39%	XXX	XXX	XXX
EBITDA Growth	158%	XXX	1667%	XXX	XXX	XXX
Rule of 40	120%	XXX	158%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	353%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	n/a	XXX	XXX	XXX
Opex per Employee	XXX	XXX	n/a	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	3%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	24%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	38%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial